Key facts
- STORM Therapeutics’s last known valuation is $90.3M (Dec 2022).
- It has raised $172.2M; the latest was Later Stage VC ($56.0M) in Apr 2026.
- Notable investors include Innovate UK, Cambridge Enterprise Ventures, M Ventures, UTokyo Innovation Platform Company, Pfizer Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for STORM Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for STORM Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About STORM Therapeutics
Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer and other immune diseases. The company's drug discovery and RNA analytics platform tackles diseases through modulating RNA-modifying enzymes and identifies novel targets and first-in-class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases, providing physicians with first-in-class therapies against RNA epigenetic targets.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2015
- Employees
- 33
- Website
- stormtherapeutics.com/
- Ownership
- Privately Held (backing)
STORM Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in STORM Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on STORM Therapeutics in its N-PORT filings yet. We sweep new filings monthly.